Skip to main content
Caplight Logo









Resistomap

Resistomap

Private
HelsinkiHealthcare & Life Scienceshttps://www.resistomap.com/

Last Round

Seed

Nov 15, 2023

Total Funding Raised

$2.17M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Resistomap is a biotechnology company that provides laboratory services and a biosecurity intelligence platform to monitor and combat environmental antimicrobial resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Environmental Monitoring, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

antimicrobial resistanceAMRenvironmental monitoringwastewater surveillanceqPCRbioinformaticsbiosecurityantibiotic resistance genesmolecular diagnosticspathogen surveillanceenvironmental healthbiotech servicesgenomic surveillancesuperbug trackingwastewater testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Resistomap Comparables

Compare Resistomap with similar companies based on industry and business-model similarity.

Resistomap comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biobot Analytics
76%
Cmbio
72%
Kraken Sense
67%

Resistomap Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 15, 2023

Key People

Founding team and executive leadership

Katie Critchlow

Advisor to CEO and COO

Executive Team

William Nurmi

CTO

Executive Team

Resistomap Investors

Notable investors and investment history

Resistomap investors
InvestorRounds
Business FinlandSeed
GaingelsSeed
Ananda VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 182% MoM, reaching 1.4K.

  • Apr 17, 2026

    Deepens collaboration with Takara Bio for AMR surveillance solutions.

Resistomap Filings

Explore SEC and related filing metadata, where available.

Resistomap filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Resistomap's valuation, stock price, and market status.

Is Resistomap a public or private company?

Resistomap is a private company.

What is the current stock price of Resistomap?

Resistomap is a private company with no public stock price. No recent secondary market data is available.

How much is Resistomap worth (valuation)?

Valuation information for Resistomap is not publicly available.

Can I buy Resistomap stock?

Resistomap shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Resistomap's last funding round?

Resistomap's most recent funding round was Seed on November 15, 2023.

Who are the main investors in Resistomap?

Key investors in Resistomap include Ananda Ventures.

Will Resistomap IPO soon?

No public IPO plans have been announced for Resistomap.

How can I track Resistomap secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Resistomap's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHelsinki
Employee Range11
Year Founded2018
Last FundingNov 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?